NYSE: PACS

PACS (PACS) Stock Analysis & Forecast

Nov 13 close

$48.32+0.32 (+0.7%)

Gekko Brief

AI summaryNov 9 close

PACS Group reported third-quarter 2026 results on 4 November, with revenue up 11.5% year-over-year to $1.5 billion and net income growth of 16.2% to $60.8 million, driven by same-store performance and strategic acquisitions. Following the results, the company raised its full-year revenue and adjusted EBITDA guidance, citing higher occupancy across established skilled nursing facilities. Separate coverage noted the addition of 43 facilities since the third quarter, including acquisitions in Florida, Texas and Eduro adding 8,400 beds, alongside CEO Jason Murray's stock sales disclosed on 7 November and a Form 144 filing by Mark Hancock proposing a sale of 186,696 shares valued at $9,418,383.80.

PACS closed at $48.77, down 1.7%, sitting above both its 50-day average of $44.73 and 200-day average of $40.07. The stock has returned 12.6% over one month and 290.8% over one year, with a 52-week range of $10.31 to $51.68. The GekkoIndex reads 51.6, placing it in the Neutral zone, while Gekko Fair Value stands at $50.37, putting the current price 3.2% below that level.

The next earnings date falls on 25 February 2027, 102 days away and outside a typical 20-trading-day holding window. Four analyst firms currently rate the stock buy, with a consensus target of $59 implying 21% upside. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows, and insufficient history exists for a seasonal read. The gap to Gekko Fair Value bears watching given recent guidance raises and acquisition activity.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

PACS price vs fair value

$51.67$48.32Nov ’25May ’26Nov ’26
Close $48.32200-day averageGekko Fair Value $51.67

PACS quick facts

Market cap
$7.67B
P/E ratio
27.3
Forward P/E
18.9
EPS, TTM
$1.76
Revenue, TTM
$5.71B
Profit margin
4.9%
Dividend yield
—
Beta
-0.14
Volume
464,269 avg 899,073
1-year return
+321.6%
Typical daily move
±4.6%
Typical 20-day move
±10.6%
50-day average
$45.23
200-day average
$40.36
Next earnings
Feb 25
Shares outstanding
158.7M
52-week range
$10.31$51.68

PACS swing-trade checklist

PACS scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $48.32 is above the 50-day ($45.23) and 200-day ($40.36) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    56, Neutral

    Reading 56 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    6.5% below

    Price is 6.5% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityno data

    No data

    Not enough years of history for a seasonal read.

A description of current data, not a recommendation. How this page works

PACS stock chart and price history

PACS closed at $48.32 on Nov 13, 2026, +321.6% over the past year, inside a 52-week range of $10.31 to $51.68.

Close50-day average200-day averageVolume
PACS share price, past year, with 50-day and 200-day moving averages and volume$10$20$30$40DecJan 2026FebMarAprMayJunJulAugSepOctNov48.32

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+1.2%
3 months
+9.0%
6 months
+28.9%
1 year
+321.6%
The full PACS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PACS in Gekko

Follow PACS through every session

Put PACS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track PACS in GekkoFree for 7 days. No credit card required.

About PACS

PACS functions as a parent company overseeing a group of businesses centered on care for patients after hospital discharge or acute treatment. This work spans running care facilities, supplying trained clinical staff, and handling the supporting services those facilities need to function. It is also recognized for housing options aimed at older adults, including focused senior care, assisted living, and independent living settings offered in particular communities.

Its operations bring together two related strands, one centered on clinical and facility-driven care, the other on residential living for seniors, giving it a presence across multiple points in a person's care journey.

Jason Murray and Mark Hancock started the company in 2013, and it now runs its operations from Farmington, Utah. Its stock trades on the NYSE under the ticker PACS.

Listed
NYSE
Sector
Health services
Industry
Hospital/Nursing management
Website
pacs.com

PACS GekkoIndex: the smart money zone

PACS’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56, in the Neutral zone, up 6.4 points over five sessions.

010056Neutral

Up 6.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying36+2.7%+4.0%+6.9%+21.0%
Accumulation194+1.3%+4.4%+5.6%+8.0%
Neutral (current zone)364+1.0%+2.1%+6.3%+20.4%
Distribution44+1.6%+1.2%+1.1%+2.2%
Selling4Too few readings yet

Average PACS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the PACS price, zone by zone.Track PACS in Gekko

Is PACS stock overvalued? Gekko Fair Value

PACS trades 6.5% below Gekko Fair Value of $51.67, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what PACS shares are worth, recalculated every trading day.

$51.67

Gekko Fair Value, Nov 14, 2026

6.5% Undervalued

At the end of Aug 2026 the price was 21.6% below the estimate.

Gekko Fair ValueShare price, month end
$52$48Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open PACS in Gekko

PACS insider and Congress trading

No open-market insider purchases were filed for PACS, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for PACS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every PACS insider filing, plotted on the chart in Gekko.Open PACS in Gekko

Congress trades last 90 days

No trades in PACS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for PACS, plotted on the chart in Gekko.Open PACS in Gekko

Buybacks

PACS has been buying back its own shares.

Bought back, quarter ended Sep 30, 2025
$440K
As a share of market cap
0.01%

From company filings.

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold PACS.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

PACS earnings: next date and track record

PACS reports on Feb 25, 2027 (102 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±16.6%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+10.7%Nov ’24−3.2%Feb ’25−2.5%May ’25+3.0%Aug ’25+81.2%Nov ’25−7.1%Feb ’26+22.1%May ’26+2.6%Aug ’26

Last earnings call, Aug 4, 2026 AI summary

What they said
PACS Group reported Q2 2026 revenue growth of 9.1% and adjusted EBITDA growth of 25% year-over-year, demonstrating meaningful margin expansion. Same-store revenue grew 5.8% with occupancy up 150 basis points; overall occupancy increased 180 basis points and skilled mix improved 100 basis points. As of June 30, PACS operated 324 facilities across 17 states with 35,631 total beds and ~48,000 employees. The company attributes performance to its locally-led, centrally-supported operating model.
Guidance
Management reaffirmed 2026 revenue and adjusted EBITDA expectations, citing continued portfolio maturation, occupancy improvement, and skill mix strengthening as key drivers. Forward guidance details were referenced in the press release and investor presentation.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 4, 2026$0.63
est $0.55
+14.5%$1.43B
est $1.41B
+1.0%+2.6%
May 11, 2026$0.64
est $0.41
+56.1%$1.42B
est $1.36B
+4.1%+22.1%
Feb 26, 2026$0.43
est $0.48
−10.4%$1.36B
est $1.38B
−1.7%−7.1%
Nov 19, 2025$0.32
est $0.45
−28.9%$1.34B
est $1.11B
+21.0%+81.2%
Aug 18, 2025$0.45
est $0.48
−6.2%——+3.0%
May 19, 2025$0.42
est $0.40
+5.0%——−2.5%
Feb 26, 2025$0.39
est $0.35
+11.7%——−3.2%
Nov 8, 2024$0.34
est $0.33
+3.0%——+10.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

PACS stock forecast and analyst price targets

Analysts’ average 12-month price target for PACS is $61.33, +26.9% from the last close, from 5 firms rating the stock in the last 90 days.

$61.33consensus 12-month target, +26.9% from the last close
Low $57High $67
Buy5
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 5 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10OppenheimerBuy, maintained$57+18.0%
Nov 5UBSBuy, reiterated$67+38.7%
Nov 5StephensBuy, maintained$64+32.5%
Oct 12UBSBuy, maintained$60+24.2%
Sep 8J.P. MorganBuy, maintained$58+20.0%
+6.3%average 20-day move after past Neutral readings
±4.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

PACS market cap and key statistics

PACS’s market cap is $7.67B, with a P/E ratio of 27.3 and revenue of $5.71B over the last twelve months.

Valuation

Market cap
$7.67B
P/E ratio
27.3
Forward P/E
18.9
EPS, TTM
$1.76
Gekko Fair Value
$51.67

Trading

Volume
464,269
Avg volume, 20 days
899,073
52-week high
$51.68
52-week low
$10.31
Shares outstanding
158.7M

Financials

Revenue, TTM
$5.71B
Profit margin
4.9%
Return on equity
26.5%
Quarterly earnings growth, YoY
+15.6%

Risk and income

Beta
-0.14
Typical daily move
±4.6%
Typical 20-day move
±10.6%

PACS peers

PACS’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
HCAHCA Healthcare−1.1%Neutral26.1% above
THCTenet Healthcare−0.8%Neutral3.0% below
UHSUniversal Health Services+1.0%Neutral11.5% below
CHEChemed−0.8%Neutral2.8% below
SGRYSurgery Partners+1.1%Distribution45.2% above
NHCNational HealthCare−1.6%Accumulation18.9% above

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Hospital/Nursing management

PACS stock FAQ

What is PACS’s market cap?

PACS’s market cap is $7.67B at the Nov 13, 2026 close of $48.32, with 158.7M shares outstanding. The shares trade on a P/E ratio of 27.3.

What is the PACS stock forecast?

The consensus analyst 12-month price target for PACS is $61.33, +26.9% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is PACS stock overvalued or undervalued?

On Gekko’s estimate PACS is undervalued: the Nov 13, 2026 close of $48.32 is 6.5% below Gekko Fair Value of $51.67. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does PACS report earnings next?

PACS is expected to report on Feb 25, 2027 (102 days away). Analysts expect earnings of $0.61 per share on revenue of $1.64B. PACS beat the earnings estimate in 5 of its last 8 reports, moving 16.6% on average across the report.

What is PACS’s 52-week high and low?

PACS’s 52-week high is $51.68 and its 52-week low is $10.31; it closed at $48.32 on Nov 13, 2026, +321.6% over the past year.

Is PACS stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See PACS the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.